Correlation between Cognitive Impairment and Peripheral Biomarkers - Significance of Phosphorylated Tau and Amyloid-β in Alzheimer’s Disease: A New Insight
Abstract:
The correlation between elevated levels of amyloid-β and phosphorylated
tau (p-tau) protein and AD is widely recognized. A rise in pTau and amyloid-
β levels aids in separating AD from other neurodegenerative conditions. In
this study, we have assessed the correlation between cognitive impairment and
peripheral biomarkers, tau and amyloid-β levels, in AD patients with mild
Alzheimer's disease in order to develop protein-based markers in a more useful
way. An enzyme-linked immunosorbent assay has been used to determine the
levels of tau and p-tau in the serum of the different groups and it has revealed
their levels to be noticeably greater in AD compared to mild AD and even higher
compared to elderly controls. Based on the cutoff levels for tau, p-tau, and
amyloid-β in patients with AD and mild AD, having high sensitivity and specificity,
which have been described in numerous studies by respective International
Research Groups (with the greatest number of pieces of available evidence),
the plasma concentration of these proteins can be used as a diagnostic indicator
for AD and mild AD. These levels may also offer a practical guide to their implementation
in the clinical routine.
The correlation between elevated levels of amyloid-β and phosphorylated
tau (p-tau) protein and AD is widely recognized. A rise in pTau and amyloid-
β levels aids in separating AD from other neurodegenerative conditions. In
this study, we have assessed the correlation between cognitive impairment and
peripheral biomarkers, tau and amyloid-β levels, in AD patients with mild
Alzheimer's disease in order to develop protein-based markers in a more useful
way. An enzyme-linked immunosorbent assay has been used to determine the
levels of tau and p-tau in the serum of the different groups and it has revealed
their levels to be noticeably greater in AD compared to mild AD and even higher
compared to elderly controls. Based on the cutoff levels for tau, p-tau, and
amyloid-β in patients with AD and mild AD, having high sensitivity and specificity,
which have been described in numerous studies by respective International
Research Groups (with the greatest number of pieces of available evidence),
the plasma concentration of these proteins can be used as a diagnostic indicator
for AD and mild AD. These levels may also offer a practical guide to their implementation
in the clinical routine.